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ABSTRACT  
Perfluoroalkylated substances (PFASs) are persistent in nature, resisting both biotic and abiotic 
degradation, resulting in the bioaccumulation of these substances in organisms, as well as 
biomagnification upwards the trophic levels in both terrestrial and marine food webs. These 
properties has made PFASs an environmental concern. 
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
transcription factors and members of the superfamily of nuclear receptors. The PPAR subfamily 
consists of three members: PPARa, PPARd, and PPARg. The different subtypes have distinct 
roles in the regulation of the lipid homeostasis, differing in tissue specific expression, ligand 
specificity, and target genes. Atlantic cod (Gadus morhua) has four different gmPpars; 
gmPpara1, gmPpara2, gmPpard and gmPparg. gmPpara1 has been demonstrated to be activated 
by some exogenous compounds including the PPARa model-agonist WY-14643, and four 
PFASs, including PFOA, PFNA, PFHxA, and PFHxS. Although the gmPpara2 subtype is also 
responsive to WY-14643, it is not activated by any of the PFASs. When aligning the protein 
sequence of gmPpara1 and gmPpara2, an extension of 14 additional amino acids (AAs) in the 
hinge region of gmPpara2 is observed. Moreover, two AAs important for the binding of WY-
14643 in a second allosteric binding site identified in the human ortholog (hPPARa) differ in 
gmPpara2 compared to gmPpara1. We hypothesized that these differences play a role in the 
observed discrepancies in the activation profiles of gmPpara1 and gmPpara2. 
In this study, site-directed mutagenesis was used to remove the 14 additional AAs in the 
hinge region, and mutate the two AAs in the putative second binding site in gmPpara2. A 
luciferase-based reporter gene assay in COS-7 cells was then used to study ligand activation of 
the gmPpars (wild types and mutants) when exposed to WY14643 and selected PFASs. Protein 
immunoblotting were used to confirm the synthesis and presence of the gmPpar variants in the 
COS-7 cells, and a cytotoxicity assay was used to monitor the cytotoxicity of the ligands. 
Four different mutants were successfully constructed. Notably, the removal of the 14 AAs in 
the hinge region had a large impact on the activation profile with WY-14643, producing a 15 
and 6 times higher fold activation in comparison to the wild type gmPpara2, and gmPpara1, 
respectively. Mutants containing the AA substitutions in addition to the deletion also increased 
the WY-14643-mediated activation, but slightly less compared to the gmPpar variant 
containing only the 14 AA deletion. Intriguingly, none of the mutants were activated by any of 
the three PFASs tested.    
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1. INTRODUCTION 
 
1.1 PERFLUOROALKYLATED SUBSTANCES (PFAS)  
In the later years, a concern about fluorinated compounds, and especially perfluoroalkylated 
substances (PFAS), has emerged (Fàbrega, Kumar, Schuhmacher, Domingo, and Nadal 
(2014)). In Norway, PFAS have especially been accentuated in the media recently because of 
how such compounds are used as functional components of ski wax used in cross-country skiing 
and biathlon. However, these substances have now been banned from use in international 
competitions. PFASs are not newly synthesized chemicals, but have been produced and 
manufactured for over 60 years. PFASs have been widely used in a variety of applications in 
both the industries and in consumer products, including water-repellent fabrics, fire-fighting 
foams, non-stick surfaces in cooking pans, and as lubricants, among others (Fàbrega et al., 
2014). In general, PFAS molecules usually have a carbon-backbone of variable length, where 
fluorines have substituted the hydrogen atoms. On one of the ends they usually have a 
functional group, such as a carboxyl- or sulfonate group. This makes PFASs amphipathic, 
where the carbon backbone constitutes the hydrophobic part, and the functional group adds 
hydrophilicity to the molecules (Fàbrega et al., 2014; Fujii, Polprasert, Tanaka, Hong Lien, & 
Qiu, 2007). Currently, the most widely used PFAS molecule is perfluorooctanesulfonic acid 
(PFOS), consisting of an eight carbon-backbone and sulfonate as its functional group, followed 
by perfluorooctanoic acid (PFOA), which possesses a seven carbon backbone and a carboxyl 
group (Fujii et al., 2007). These PFASs, together with perfluorononanoic acid (PFNA), which 
has a nine carbon backbone and a carboxyl group (Jantzen, Annunziato, Bugel, & Cooper, 
2016), have been studied in this thesis (Fig. 1.1). 
 
PFASs have shown to be persistent in the environment, resisting both biotic and abiotic 
degradation. This makes PFASs accumulate in nature, where they are prone to long 
transportation by atmospheric circulation and ocean currents. It appears as the majority of 
released PFASs end up in the oceans, potentially posing a threat to marine species and 
ecosystems (Prevedouros, Cousins, Buck, & Korzeniowski, 2006). Here, the PFASs can 
bioaccumulate in organisms, and biomagnify upwards the trophic levels (Boisvert, Sonne, 
Rigét, Dietz, & Letcher, 2019; Simonnet-Laprade et al., 2019). PFASs have been detected in 
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remote areas, including the Arctic where it is released from atmospheric deposition and 
transportation by ocean currents. The presence of PFAS in the Arctic has been documented by 
its detection in several organisms living there (Muir et al., 2019). 
 
Figure 1.2: Structures of nonanoic acid, WY14643, and selected PFASs. The structures of WY-
14643, nonanoic acid (saturated fatty acid), PFOA, PFNA and PFOS are shown as indicated. Structures 
were found at Chemspider and drawn with ChemDraw. 
 
In 2008/2009 samples of Atlantic cod from 15 Norwegian fjords were investigated, and PFASs 
were detected in cod liver and blood, including PFOA, PFNA and PFOS. Significantly higher 
levels of PFASs in the eastern fjords compared to the western and northern fjords of Norway 
were revealed (Valdersnes, Nilsen, Breivik, Borge, & Maage, 2017). PFASs have also been 
detected in blood samples and liver samples from Atlantic cod living in the Baltic Sea. PFOS 
and perfluorooctanesulfonamide (PFOSA) were predominating congeners in those samples, but 
also PFOA and perfluorodecanoate (PFDA) were detected (Falandysz et al., 2007; Schultes, 
Sandblom, Broeg, Bignert, & Benskin, 2020). Low levels of PFASs have also been detected in 
halibut (Hippoglossus hippoglossus) along the Norwegian coast (Muir et al., 2019). 
 
Since PFASs have emerged as an environmental concern, the most used congeners, including 
PFOA and PFOS, their salts, and related compounds, have been included in the Stockholm 
Convention on Persistent Organic Pollutants. Moreover, the Norwegian Environmental Agency 
has PFASs on their list of prioritized environmental pollutants, which make them included in 
all surveillance and monitoring programs in Norway. PFOS is also on the OSPARs List for 
Chemicals of Priority Action (COMMISION, 2019).  
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1.2 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS)  
The peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription 
factors that are members of the superfamily of nuclear receptors (NRs). When PPARs were first 
discovered in rodents, they were seen as receptors that promote peroxisome proliferation and 
increased the number of peroxisomes in the cells, hence named peroxisome proliferator-
activated receptors (I. Issemann & S. Green, 1990). Later it was discovered that PPARs had a 
broader functional role than just proliferating peroxisomes. PPARs are also involved in other 
physiological processes, such as cell differentiation, development, and importantly, as a key 
regulator of the lipid and energy homeostasis (Dreyer et al., 1992; Isabelle Issemann & Stephen 
Green, 1990).  
 
PPARs are divided into three subtypes, PPARa (NR1C1), PPARd (NR1C2) and PPARg 
(NR1C3) (Hong, Xu, & Zhai, 2018). The sub-types have different physiological roles in the 
energy metabolism and fat storage, which also include tissue specificity and target gene 
repertoire (Fig.1.2). The PPARs are mainly found in metabolically active tissues, such as heart, 
kidney, liver and muscle. They sense changes in the dietary lipids and modulate the gene 
expression of different target genes. In mammalian species it has been shown that PPARa has 
an essential role in fatty acid (FA) uptake and metabolism, including β-oxidation of FAs. The 
FA oxidation provides energy to peripheral tissues (Tyagi, Gupta, Saini, Kaushal, & Sharma, 
2011). PPARd is also important for FA oxidation, promoting FA metabolism, and suppresses 
macrophage-derived inflammation. It activates different genes important for β-oxidation and 
energy dissipation through uncoupling of the mitochondria. PPARd also plays a key role in the 
cholesterol metabolism (Grygiel-Górniak, 2014; Tyagi et al., 2011). PPARg is involved in 
energy storage and glucose metabolism, by regulating insulin sensitivity. It is involved in 
regulating the expression of genes necessary for the differentiation of fibroblasts into 
adipocytes. Its most widely studied ligand is thiazolidinedione (TZD), which is a drug used to 
treat type 2 diabetes (Tyagi et al., 2011). Human PPARg can also be activated by derivates of 
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Figure 1.2: Metabolic regulation by the different PPAR subtypes. PPARa, PPARd and PPARg 
collectively regulate and maintain lipid and glucose homeostasis. In humans, PPARa regulate fatty acid 
(FA) oxidation in the liver and muscle. PPARg controls fat synthesis and storage in the liver, as well as 
the insulin sensitivity in the muscles. PPARd also regulates and promotes FA oxidation in muscle, but 
also in adipose tissues, and regulates thermogenesis. Picture source: (Lehninger et al., 2008). In Atlantic 
cod there are four different Ppars, as cod possesses two Ppara paralogs in addition to Pparg and Ppard. 
Hovewer, the exact functions of the Ppar subtypes in teleosts are not yet described. 
 
While the PPARs in humans and rodents are widely studied, much less is known about the exact 
function of Ppar subtypes in fish. Nevertheless, the Ppars have been cloned from many teleosts, 
and sequence alignments and phylogenetic analyses have confirmed that the fish Ppars are 
homologs of the mammalian PPARs (Leaver et al., 2005). In teleost species all three subtypes 
of Ppars have been identified, but some species possess two paralogs of Ppara, e.g Japanese 
puffer (Fugu rubripes) (Maglich et al., 2003), green spotted puffer (Tetraodon nigroviridis) 
(Metpally, Vigneshwar, & Sowdhamini, 2007), loach (Misgurnus anguillicaudatus) (Liang, 
Gao, Li, & Cao, 2016), zebrafish (Danio rerio) (Den Broeder, Kopylova, Kamminga, & Legler, 





1 In this thesis I follow the nomenclature, where proteins from mammals are written in all 
capitals ("HGNC Guidelines,"), whereas short names of fish proteins are written with only the 
first letter in capital (Nathan Dunn, 2019).   
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1.2.1 ENDOGENOUS AND EXOGENOUS LIGANDS FOR PPAR 
Since the three types of PPARs have different roles in the lipid metabolism and storage, they 
are also activated by different ligands. In comparison to other NRs, the PPARs ligand binding 
pocket is 3-4 times larger (1300-1400 Å). This may cause other non-endogenous ligands to bind 
PPARs with relatively low affinity. The shape of their ligand pocket also determines which 
ligands they can bind (Xu et al., 2001). The interior of the entrance to the ligand binding site is 
mainly hydrophobic, in agreement with the hydrophobicity of the natural ligands (Zoete, 
Grosdidier, & Michielin, 2007). The ligands recognized by PPARa are usually fatty acids and 
their derivates, like eicosanoids. Exogenous ligands that have been demonstrated to bind 
PPARa include fibrates, which is used for treatment of hypertriglyceridemia and mixed 
dyslipidemia (Derosa, Sahebkar, & Maffioli, 2018; Grygiel-Górniak, 2014). A well-known 
synthetic model agonist for the human PPARa is pirinixic acid (also known as 4-chloro-6[(2.3-
dimethylphenyl)amino]-2-pyrimidinyl]thio-acetic acid or WY-14643) (Figure 1.1). WY-14643 
has been used as an anti-hypercholesterolemic agent in humans where it promotes peroxisome 
proliferation.  It is also used as an agonist in functional studies of PPARa (J. Z. Zhang & Ward, 
2010; W. Zhang, Sakai, Fujiwara, & Hatano, 2017). PPARd is also activated by unsaturated 
fatty acids, carbaprostacyclin, and the synthetic aromatic ether, GW501516 (Billin, 2008). For 
PPARg no highly specific endogenous ligand is known, but it can be activated by 
prostaglandins and eicosanoids.  Of exogenous and synthetic PPARg ligands there are several, 
including rosiglitazone, pioglitazone, troglitazone and ciglitazone, which are drugs that can be 
used in treatment of diabetes and cardiovascular diseases (Grygiel-Górniak, 2014; Guan, 
Ishizuka, Chui, Lehrke, & Lazar, 2005; Shang et al., 2018).  
 
The PFASs share structural similarities to fatty acids (FA), which also have a hydrophobic 
carbon backbone of variable length with a hydrophilic carboxylate group at the end. In Figure 
1.1 the structure of WY-14643, the three PFASs used in this study, as well as a saturated fatty 
acid (nonanoic acid) are shown. Accordingly, it has been found that hPPARa can be activated 
by PFOA, PFOS, propanoic acid (PMPP), ammonium perfluoro(2-methyl-3-oxahexanoate) 
(PMOH), perfluorohexanoic acid (PFHxA), perfluorohexanesulfonic acid (PFHxS), and 
perfluorobutanoic acid (PFBA). Furthermore, perfluorinated carboxylic acids have been shown 
to be agonists with higher efficacy than perflurorinated sulfonic acids (Behr, Plinsch, 
Braeuning, & Buhrke, 2020). There are also species differences regarding PPARs and 
activation by PFAS molecules. Studies conducted with mouse and human PPARa have 
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demonstrated that the receptors can be significantly activated by several PFASs, including 
PFOA, and PFOA was found to activate the mouse PPARd as well. PFOS was shown to activate 
the mouse PPARa, but not the human PPARa. Taken together, this demonstrates that PPARs 
are potential targets for PFASs, which therefore may modulate their activities, including the 
regulation of their target genes (Schlezinger et al., 2020; Takacs & Abbott, 2007). 
   
1.2.2 FUNCTIONAL DOMAINS OF PPARS 
PPARs have a canonical domain structure similar to other NRs, including five functional 
domains: A/B, C, D, E, and F (Fig. 1.3). The N-terminal A/B domain has a ligand-independent 
activation function (AF-1), which is responsible for receptor activation through 
phosphorylation (Werman et al., 1997). This is followed by the DNA-binding domain (DBD) 
in the C region, possessing two zinc fingers required for binding to peroxisome proliferator 
response elements (PPREs) in the promotor region of their target genes. The D domain  includes 
a dimerization interface, which can dimerize to e.g. RXR to make a heterodimer. Situated 
between the DBD and LBD, the hinge (D region) provides flexibility in the PPAR receptors 
(Germain, Staels, Dacquet, Spedding, & Laudet, 2006; Kota, Huang, & Roufogalis, 2005). The 
E-region is the ligand-binding domain (LBD), responsible for specific recognizing, binding of 
ligands and activating the receptor (Kota et al., 2005). The ligand-dependent activation function 
(AF-2) is located in the F domain, which aid the recruitment of co-factors to assist the gene 
transcription of target genes (Kota et al., 2005; Tyagi et al., 2011; Zoete et al., 2007). 
 
Figure 1.3: Functional domains of peroxisome proliferator-activated receptors. A linear 
representation of the functional domains of the peroxisome proliferator-activated receptor. 
 
   14 
1.2.3 MECHANISM OF LIGAND ACTIVATION OF PPAR 
Unliganded PPAR is located in the nucleus. When PPAR is activated by endogenous or 
exogenous ligands it heterodimerizes with 9-cis-retinoic X receptor (RXR), forming the 
heterodimer PPAR:RXR (Fig. 1.4). The binding of ligands also facilitates the release of co-
repressors associated with PPAR, and the recruitment of cellular co-activators. The PPAR:RXR 
heterodimer will bind to PPREs in DNA allowing the initiation of the transcription of target 
genes (Kliewer, Umesono, Noonan, Heyman, & Evans, 1992). The function of PPAR is 
controlled at multiple levels, including ligand availability, protein-protein interactions, receptor 
abundance and stability, as well as posttranslational modifications (Kota et al., 2005; Patel, 
Truant, Rachubinski, & Capone, 2005).   
 
 
Figure 1.4: Mechanism of ligand activation of the peroxisome proliferator-activated receptor 
(PPAR). Unliganded PPAR is located to the nucleus. When PPAR recognizes and bind to a ligand (L) 
(1), the receptor will heterodimerize with retinoid X receptor (RXR) (R=intracellular RXR ligand) to 
form the heterodimer (PPAR:RXR) (2). The binding of ligand also facilitates release of co-repressors 
(3) and recruitment of co-activators (4). The PPAR:RXR heterodimer together with the co-activators 
binds to peroxisome proliferator response elements (PPREs) in the DNA (5) facilitating transcription of 
various PPAR target genes (6). 
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1.2.4 PPARS IN ATLANTIC COD 
Four different Ppar-encoding genes have been identified in Atlantic cod, i.e. gmppara1, 
gmppara2, gmppard, and gmpparg (Eide et al., 2018; Sofie Söderstrøm, 2020), but their exact 
function is not known. However, the Atlantic cod Ppars were recently cloned and studied with 
regard to their phylogeny, ligand-activation, and tissue specific distribution (Sofie Söderstrøm, 
2020). Earlier, PFOA and PFNA, but not PFOS, were shown to activate gmPpara1 in Atlantic 
cod, indicating that these compounds may act as endocrine disruptors by being able to modulate 
the energy metabolism (S.Söderstrøm, 2017). Notably, it was also demonstrated that gmPpara2 
is not responsive to activation by PFASs (S.Söderstrøm, 2017). Comparison of the gmPpara1 
and gmPpara2 primary structures demonstrated that gmPpara2 have an additional stretch of 14 
amino acids (AAs) in its hinge region that is not present in gmPpara1 or hPPARa (Fig. 1.5). In 
silico modeling of the gmPpara1 and gmPpara2 3D structures suggested that this extended 
stretch of AAs forms an extended loop in the region between H1 and H3 in the gmPpara2 
receptor (Fig. 1.6). This extended loop may introduce instability to the receptor structure that 
may have an impact on the function of gmPpara2. It has been demonstrated that the model-
agonist WY-14643 binds in the canonical binding pocket of hPPARa. WY-14643 interacts with 
hPPARa by a hydrogen-bond network with the carboxylic functional group in the upper part of 
the site, and hydrophobic interactions with the site further down within its hydrophobic tail. It 
has also been confirmed that WY-14643 molecules can bind to a second allosteric site present 
in the ligand-binding pocket of the hPPARa receptor. This secondary binding site is positioned 
between helices 2 and 3 of the protein (H2 and H3), and it has been proposed that binding of 
WY-14643 to this second binding site stabilizes the structure of this region of the protein, which 
has been shown to be very flexible (Bernardes et al., 2013).  
 
Importantly, the AAs involved in binding of WY-14643 in the primary binding site in the 
ligand-binding pocket of hPPARa are conserved in both gmPpara1 and gmPpara2, which 
correspond to S280, Y314, H440, and Y464 in hPPARa (Fig. 1.5).  Accordingly, both gmPpara 
subtypes were activated by WY-14643, but gmPpara1 was the most sensitive receptor and 
produced the highest efficacy (S.Söderstrøm, 2017). The four AA residues constituting the 
putative second binding site for WY-14643 are also conserved in gmPpara1, with the exception 
of the conservative substitution of K278->R278 (Fig. 1.5). On the other hand, this site appears 
to be disrupted in gmPpara2, where two of these residues are substituted with AAs possessing 
other chemical properties, i.e. K278->G278 and H286->L286. These discrepancies, including 
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both the additional stretch of 14 (AAs) in the hinge region and the differences in the putative 
second binding site, may have an impact on the observed differences in both efficacy and 
potency of WY-14643 towards, and the activation by PFAS molecules in gmPpara1 compared 
to gmPpara2 (S.Söderstrøm, 2017). 
 
 
Figure 1.5: Multiple sequence alignment of human PPARa, Atlantic cod Ppara1 and Ppara2. The 
areas highlighted with red squares show the extended stretch of AA in the hinge region of gmPpara2, as 
well as the AAs that have been identified to constitute the second binding site for WY-14643 in hPPARa. 
The residues highlighted in green are conserved AAs important for binding of WY-14643 in the 
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Figure 1.6: 3D-model of the hinge-region and ligand-binding domain of gmPpara1 and gmPpara2. 
The LBDs of the two receptors share structural features to other NRs. The hinge region between H1 and 
H3, which contain the additional stretch of 14 AA in gmPpara2 is shown in orange, and is, thought to 
produce an extended loop in comparison to gmPpara1. This extension is situated near both the LBP and 
the coregulator binding groove (AF-2 motif). The figure was made by collaborator Prof. Roland Stote, 
University of Strasbourg, France. 
 
1.3 ATLANTIC COD AS A MODEL SPECIES 
Atlantic cod (Gadus morhua) is a teleost that is abundant in the North Atlantic Ocean and the 
Barents Sea, with several populations differing in geographic distribution, life history strategy, 
and genetics. The north east Atlantic cod is the largest cod population in the world, which is 
also commercially highly important for Norwegian fisheries (Link, Bogstad, Sparholt, & Lilly, 
2009).  
 
The annotation of the Atlantic cod genome facilitates the ability to combine proteomics, 
genomics and metabolomics to investigate how cod respond to different environmental 
pollutants on several biological levels (Karlsen et al., 2011; Link et al., 2009; Star et al., 2011). 
Due to the position of Atlantic cod in the marine food chains it has a key role in coastal and 
pelagic ecosystems, and is often used as an indicator species in pollution monitoring programs 
(Link et al., 2009). Different environmental contaminants have been found to accumulate in 
cod and affect biomarker responses (Dale et al., 2019; Ono et al., 2019; Yadetie et al., 2016). 
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For instance, PCBs which is now forbidden to use, bioaccumulate and biomagnify in the food 
chain, and in vivo studies have revealed that this compound may affect the lipid metabolism 
cytoskeletal remodeling, cell cycle and cell adhesion in Atlantic cod (Yadetie et al., 2017).  
 
1.4 AIM OF STUDY 
Previous findings have shown that the Atlantic cod gmPpara1 and gmPpara2 have distinct 
differences in their primary structures (S.Söderstrøm, 2017). Among the major difference 
between the cod Ppara1 and Ppara2 is a 14 AA indel in the hinge region (AA 266-279), 
putatively producing an extended loop between H1 and H3 in the gmPpara2 protein structure 
that could possibly destabilize this region (Fig. 1.6). Structural analyses in silico suggested that 
this indel could contribute to the observed discrepancies in the activation profiles produced in 
luciferase-based reporter gene system when exposed to various ligands, including both PFASs 
and the WY-14643 model agonist. Furthermore, the AAs shown to constitute a second binding 
site for the WY14643 model-agonist in the hPPARa are different in the gmPpara protein 
sequences, although this second binding site has not yet been confirmed to bind WY-14643 in 
the gmPpars. In gmPpara1, two of the AAs that are part of this site are arginine (R278) and a 
histidine (H286), which both are reactive AAs. In gmPpara2 these AAs have been substituted 
to the more aliphatic and non-reactive glycine (G278) and leucine (L286). Moreover, we 
hypothesize that the extended AA stretch in hinge region of gmPpara2, in addition to the 
differences in AA in the putative second binding site for WY-14643, can affect the 
transactivation of gmPpara2 in vitro. Thus, in order to assess these differences, the stretch of 
14 AA in gmPpara2 will be deleted, and in addition the AAs constituting the putative second 
WY14643-binding will be mutated to become similar to gmPpara1. To functionally 
characterize the receptors, the transactivation profiles of the wild type and mutated gmPpara 
proteins will be analyzed in a luciferase-based reporter gene assay with the model-agonist WY-
14643 and three PFASs, including PFOA, PFNA and PFOS, where PFOA and PFNA were 
previously shown to activate gmPpara1, but not gmPpara2. We hypothesize that when 
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2. MATERIALS 
 
2.1 CHEMICALS AND REAGENT 
Table 2.1: Chemicals and reagents used during the master thesis.  
Name CAS # Supplier 
10x Loading Buffer 
2-log DNA ladder 




Ampicillin sodium salt 
(Adenosine 5´-triphosphate disodium salt(ATP) 
β-mercaptoethanol  
Bovine Serum Albumin (BSA) 
3-((3-cholamidopropyl) dimethylammonio)-1-
propanesulfonate (CHAPS)  
Charcoal stripped Fetal bovine serum 
Coenzyme – A 
Disodium hydrogen phosphate 
D-luciferin potassium salt 
Dimethyl sulfoxide (DMSO) 
Dulbecco's Modified Eagle's Medium (high 
glucose, with phenol red) 
Dulbecco's Modified Eagle's Medium (high 
glucose, without phenol red) 
 (Ethylenediaminetetraacetic acid disodium salt 
dehydrate) EDTA 
 (Ethylene glycol-bis(2-aminoethylether)-
N,N,N´,N´-tetraacetic acid) EGTA 
Ethanol 





Magnesium carbonate hydroxide pentahydrate -  
Magnesium chloride hexahydrate -  
Magnesium sulfate heptahydrate 
Methanol 
ONPG (2-Nitrophenyl β-D-galactopyranoside) 







































New England Biolabs 
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PFNA (Perfluorononanoic acid) 
PFOA (Perfluorooctanoic acid) 
PFOS (Perfluorooctanesulfonic acid)  
Penicillin streptomycin  
Phosphate-buffered saline (PBS) 10X 
PMSF (Phenylmetanesulfonyl fluoride) 
Potassium Chloride 
Precision Plus Protein™ Kaleidoscope™ 
Resazurin sodium salt 
SOC Outgrotwth Medium 
Sodium Chloride 
Sodium phosphate monobasic monohydrate 
Sodium pyruvate solution  
TransIT ®-LT1 
Tricine 
Tris-HCl pH 7.8  
Triton® X100 
Tryptone plus 












































Table 2.2: Software and online tools used during the thesis. 




Excel 2020 (version 16.35) 
ExPASy Translate tool 
 
ExPASy Compute pI/Mw tool 
 
Jalview 2.11.1.0 




PowerPoint 2020 (version 16.35) 




Operate plate reader  
Data analysis and statistics 
Sequence translation 
 
Computation of theoretical 
Mw 
Alignments 















Martin, Clamp, and Barton 
(2009) 
GraphPad Software 
New England Biolabs 
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2.3 EQUIPMENT AND INSTRUMENTS 
Table 2.3: Equipment and instruments utilized during the thesis.  
Instrument Application  Supplier 
Bürker haemocytometer 
ChemiDoc™ XRS+ System 
Doppio Thermal Cycler 
EnSpire 2300 Multimode Reader 




Ultraspec 10 Cell density meter 
Z 216 MK microliter centrifuge 
Cell counting 
Gel scanning 




















Table 2.4: Primers used for creating mutants of gmPpara2 







g274c g275g c276c FWD 
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2.5 PLASMIDS 
Table 2.5: Plasmid concentrations and purities used for LRA, cytotoxicity measurements and 
SDS-PAGE. 


































2.6 COMMERCIAL KITS 
Table 2.6: Commercial kits utilized during the thesis. 
Name Usage Supplier 
Q5® Site-Directed Mutagenesis kit 
QuikChange II Site-Directed 
Mutagenesis kit 
NucleoBond® Xtra Midi plasmid 
purification kit 
NucleoSpin® Plasmid EasyPure kit 








Protein detection (Western 
blotting) 
Protein detection (Western 
blotting) 










2.7 BACTERIA AND CELL LINES 
Table 2.7: Bacteria and cell lines utilized during the thesis.  
Cell line Application  Supplier/reference 
COS-7 cells 
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2.8 GROWTH MEDIA 
Table 2.8: Lysogeny Broth (LB) growth media 



















iAdded after autoclaving for 30 min at 121oC.  
 
Table 2.9: Cell Freezing media for COS-7 
cells  
Table 2.10: Growth media for cultivation of 
COS-7 cells 
Component Conc. Component Conc. 
Dulbecco’s modified Eagle 
medium (DMEM) with phenol red 











5 % (v/v) 
Dulbecco’s modified Eagle 
medium (DMEM)i 











iCell growth media was made with DMEM with phenol red, while phenol red-free DMEM was used in 
exposure media.  
iiCharcoal-stripped FBS was used in exposure media.  
 
2.9 BUFFERS AND SOLUTIONS 
 
2.9.1 AGAROSE SOLUTIONS 
Table 2.11: Tris borate 
EDTA (TBE) buffer 
Table 2.12: Agarose gel 
components 
Table 2.13: Agarose gel 
components 
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2.9.2 LUCIFERASE REPORTER GENE ASSAY (LRA) 
Table 2.14: Cell lysis base buffer (1X)                              Table 2.15: Cell lysis reagent solution 
Component Conc. Component Conc. 





















Table 2.16: β-galactosidase base buffer (10 X)    Table 2.17: β-galactosidase reaction solution 


















Table 2.18: Luciferase base buffer (4X, pH 7.8)                     Table 2.19: Luciferase reaction solution 





















                                                                                                                                                                   iAdded just before use 
 
2.9.3 CELL VIABILITY
Table 2.20: L-15/ex 
Solution A 
Table 2.21: L-15/ex 
Solution B 
Table 2.22: L-15/ex 
Solution C 
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Table 2.23: L-15/ex solution for cell viability 
measurements 
Table 2.24: Viability solution with resazurin 
and CFDA-AM 
Component Conc. Component Conc. 
Solution A (Table 20) 
Solution B (Table 21) 


















Table 2.25: 5X SDS-PAGE Sample Buffer 
(5XSB)  
Table 2.26: Lysis Reagent for preparation of 
proteins for SDS-PAGE 
Component Conc. Component Conc. 





250 mM  
10 %  
30 %  
5 %  
0.02 %  
5X sample buffer 
10 X PBS pH 7.4 







Table 2.27: SDS-PAGE 10 % Resolving Gel and 4 % Stacking Gel 
Component Conc. Conc. 
Tris-HCl (pH 8.8) 
Tris-HCl (pH 6.8) 
Acrylamide/bisacrylamide 
Sodium dodecylsulfate (SDS) 
Ammonium persulfate (APS) 














Table 2.28: 1 X SDS-PAGE 
running buffer 
Table 2.29: 1 X Blotting 
Buffer 
Table 2.30: 5X Tris Buffer 
Saline (TBS) (pH 7.5) 
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Table 2.31: Protein immunoblotting washing 
solution 0.05 % TBS-Tween 
Table 2.32: Blocking solution with 5 % Dry 
Milk 
Component Conc. Component Conc. 












Table 2.33: Antibodies used for western blotting during the thesis. 
Name Supplier 
GAL4 (DBD) (RK5C1), mouse monoclonal 
Anti-β-actin, monoclonal 
Horseradish Peroxidase linked whole antibody from sheep 
Anti-mouse IgG, polyclonal 
Santa Cruz Biotechnology 
Abcam 








3.1 EXPERIMENTAL OUTLINE 
 
 
Figure 3.1: Workflow overview. Site-directed mutagenesis was used to generate four different 
gmPpara2 mutants, which were verified with Sanger sequencing.  Highly pure plasmids (Table 2.5) 
were prepared with midi-preparations for the luciferase reporter gene assay (LRA), and the integrity of 
plasmids was assessed by agarose gel electrophoresis prior to use. In the luciferase reporter gene assay, 
COS-7 cells were seeded and transiently transfected with plasmids encoding wt and mutated gmPparas, 
as well as reporter and control plasmids. The transfected COS-7 cells were exposed to selected ligands 
(WY-14643, PFOA, PFNA and PFOS), and luciferase activity was recorded the next day. To assess the 
expression of gmPpar-fusion proteins in the COS-7 cells, the transfected cells were harvested, proteins 
separated by SDS-PAGE and fusion proteins detected by protein immunoblotting. The cytotoxicity of 




3.2 CONSTRUCTION OF ATLANTIC COD PPARA2 MUTANT PLASMIDS 
 
3.2.1 PREPARATION OF PLASMIDS ENCODING MUTATED GMPPARS 
Eukaryotic expression plasmids encoding the Atlantic cod Ppara1 and Ppara2 (pCMX-
GAL4_gmPpara1/2) (previously prepared by Sofie Söderstrøm Oct. 2017), were used as 
templates for construction of plasmids encoding mutated gmPpars. In these pCMX-
GAL4_gmPparx plasmids, the hinge region and the LBD of the gmPparx receptor is fused N-
terminally to the DBD of yeast GAL4, encoding GAL4-DBD-gmPparx-LBD fusion protein. 
 
3.2.2 SITE DIRECTED MUTAGENESIS 
Site directed mutagenesis (SDM) is an in vitro technique that allows for changing single or 
multiple nucleotides, as well as removing or inserting nucleotides in a DNA sequence to alter 
the encoded AA sequence, or change the reading frame (Agilent). In this study two different 
mutagenesis kits was used to perform two different types of mutations. The NEBQ5 kit was 
used to delete a stretch of 14 AAs (AA 266 to 279) in gmPpara2, while the Agilent QuikChange 
kit was used for making two point mutations in gmPpara2, i.e. to change G278>R278 and 
L286>H286. 
 
3.2.2.1 DELETION OF 14 AAS IN GMPPARA2 
Primers were designed using the online tool of NEBQ5 NEBase Changer 
(https://nebasechanger.neb.com, April 2020). The primers used are shown in Table 2.3. 
Deletions to pCMX-GAL4_gmPpara2 were performed using the NEBQ5 SDM kit reaction 
solutions as described in Table 3.1, and a temperature cycle as described in Table 3.2. Prior to 
circularization of the linear PCR product.  
The linear amplification products were ligated with NEB Q5 SDMs KLD enzyme mix, which 
contains a kinase to phosphorylate the 5’-end of the PCR-product, a ligase to ligate the two ends 
of the linear PCR product together, and DpnI, which cleaves template DNA containing 
methylated adenine (mA) at the dam sequence GmA | TC. The ligation was performed at RT for 
five minutes. 
 
Table 3.1: Reaction solution for NEB Q5 
SDM deletion experiment 
Table 3.2: Thermal cycle program for NEB 
Q5 SDM deletion experiment 
Reagent 25 μL 
RXN 
Conc. Step Temp. 
(oC) 
Time 
Q5 Hot Start High-
Fidelity 2X Master Mix 
10 μM Fwd Primer 

































Transformation and selective cultivation of transformed E.coli 
To transfer the circular mutated DNA to bacteria, NEB alpha E. coli competent cells were 
transformed by heat shock treatment. The transformation mixture was prepared with 5 μL of 
ligation mixture and 25 μL of competent E. coli cells. The cells were kept on ice for 30 min to 
ensure an abrupt temperature change. The heat shock was performed in a 42 oC water bath for 
30 sec, immediately incubating the cells on ice for five minutes. To cultivate the transformed 
cells, 950 μl SOC medium was added to each reaction, and incubated at 37oC for 1 hr while 
shaking. Subsequently, volumes of 10 μL and 100 μL of the transformation reaction were 
transferred to LB-agar plates (100 μg/mL amp), and incubated ON at 37oC. Positive 
transformants were selected for by their ampicillin-resistance, provided by the Ampr-gene in 
the cloning vector. Five colonies were selected and propagated in 3 mL LB-cultures, 100 μg/mL 
amp. The cultures were incubated ON at 37 oC, at 100 rpm shaking. These colonies were also 
reseeded on a new agar plate for further downstream use. The 3 mL cultures were used as 
templates to purify potentially mutated plasmids, and Sanger DNA sequencing (Method 3.8) 
was performed to evaluate the success of the SDM reactions. Plasmids from one clone encoding 
the desired deletion were chosen for further work. This mutant plasmid was named 
pCMX_GAL4_gmPpara2_DEL.  
 
3.2.2.2 SINGLE AMINO ACID SUBSTITUTIONS IN GMPPARA2_DEL 
To obtain the single AA changes in gmPpara2, point mutations were performed in the 




were designed using the online tool, the QuikChange® Primer Design Program 
(https://www.agilent.com/store/primerDesignProgram.jsp). Two AAs were targeted for 
substitution, G278 and L286. The goal was to produce two single AA (either R278 or H286) 
mutants and one double AA (both R278 and H286) mutant. Three reactions were prepared 
according to Table 3.3. The PCR was run as shown in Table 3.4.  
 
Table 3.3: Reaction solution for Agilent 
QuikChange Mutagenesis. 
Table 3.4: Thermal Cycle program for 
QuikChange SDM point mutations. 
Reagent 25 μL RXN Conc. Step Temp. 
(oC) 
Time 




























DpnI digestion of template plasmid 
To each reaction 1 μL DpnI restriction enzyme (10 U/ μL) were added, and incubated for 1 hr 
at 37oC, to digest parental plasmid DNA. 
 
Transformation of competent E. coli cells and selective cultivation of transformed E.coli 
The DpnI-digested SDM-products were transferred to StrataCloneSoloPack Competent Cells 
by heat shock transformation. The transformation mixtures were prepared by adding 1.5 μL of 
DpnI-digested SDM-product to 33 μL of competent cells. The transformation reactions were 
kept on ice for 30 min, then heat shocked at 42 oC in a water bath for 30 seconds, and 
immediately placed on ice for 5 minutes. To the heat shocked cells were added 250 μL SOC 
growth medium and incubated for 1 hr while shaking at 37oC.  25 μL and 200 μL reaction 
solution was plated on LB-Amp agar plates that were incubated ON at 37oC. 3 mL LB-Amp 
cultures were cultivated for plasmid preparation and purification (Methode 3.3.1). In total four 




3.3 PLASMID DNA PURIFICATION 
DNA purification was used to purify plasmids for later experiments. Small-scale plasmid 
preparation (mini-prep) (3.3.1) is a method suitable for purifying smaller amounts of DNA, e.g. 
plasmids for DNA sequencing. Medium-scale plasmid preparations (midi-prep) (3.3.2) is a 
method suitable for purifying larger amounts of highly pure plasmid DNA (pDNA), e.g. for the 
luciferase reporter gene assay LRA. The principle of the two methods are very similar, but 
midi-prep contains an additional concentrating and purifying step involving isopropanol 
precipitation (concentrating) and ethanol wash (desalting). 
Transformed E. coli was inoculated in 3 or 200 mL LB-medium cultures containing 100 μg/mL 
ampicillin and cultivated overnight (37oC, 250 rpm). The bacteria were harvested by 
centrifugation (3500xg, 5 minutes) and the pellet was resuspended in resuspension buffer 
containing RNase to degrade RNA. The DNA content of the E. coli host cells was liberated by 
SDS/alkaline lysis, followed by neutralization with a buffer containing acetate to make the 
plasmid DNA go back to its supercoiled conformation and ensure appropriate conditions for 
binding of plasmid DNA to the silica membrane. Chromosomal DNA, proteins and cell debris 
were precipitated by centrifugation, while the plasmid containing supernatant was applied to a 
silica-based column under high ionic conditions to bind pDNA. The membranes were washed 
with an ethanolic buffer to remove contaminations, such as macromolecular cellular 
components, salts, and metabolites. The pure plasmid DNA was eluted with an elution buffer 
with low ionic strength and slightly alkaline pH (Buffer AE, (5mM Tris/HCl, pH 8.5) for the 
mini-prep protocol. Midi-prep had an additional purification step where the DNA was 
precipitated with isopropanol and centrifuged, the pellet was washed with ethanol and dried. 
The pellet was dissolved in AE-buffer. The plasmid DNA concentrations were measured with 
Nanodrop.   
 
3.3.1 SMALL-SCALE PLASMID PREPARATION 
Small-scale plasmid preparations were performed to produce plasmids for evaluation of the 
SDM success by DNA sequencing. Selected E. coli transformants were inoculated ON. For 
purification of plasmid DNA, a NucleoSpin ® kit from Macherey-Nagel was used and the 





3.3.2 MEDIUM-SCALE PLASMID PREPARATION 
For purification of effector-, control-, and receptor plasmids used in the LRA (3.4), the Plasmid 
DNA purification NucleoBond® PC100 kit from Macherey-Nagel was used. E. coli was 
transformed with either the effector-, control- or receptor plasmid and inoculated separately. 
The density of the culture was measured at 600 nm using a cell density meter (Ultraspec 10 
Cell Density meter, Amersham Biosciences). The ODV=200 was calculated (ODV=Optical 
density * culture volume (mL)). The plasmids were harvested, isolated, and purified according 
to the protocol. Purified plasmids were dissolved in 250 µL AE buffer. 
 
3.4 LUCIFERASE REPORTER GENE ASSAYS (LRA) OF GMPPARS  
A COS-7 cell based UAS/GAL4-DBD luciferase reporter gene assay (LRA) was used to 
measure ligand activation of the gmPpars exposed to selected test compounds. A reporter 
plasmid (MH(100)x4tkluc) containing the luciferase reporter gene, a receptor plasmid (pCMX-
GAL4_gmPparax), and a β-galactosidase-encoding control plasmid (pCMV_β_Gal) were 
transiently co-transfected into COS-7 cells. In the reporter plasmid the transcription of 
luciferase is controlled by repeated upstream activation sequences (GAL4-UAS) in the 
promotor region. The receptor plasmid encodes the fusion protein GAL4-DBD-gmPparx-
hinge-LBD. Upon binding of an agonist to the LBD of the fusion protein, a conformation 
change occurs changing the GAL4_DBD_gmPparLBD fusion proteins from a non-active to an 
active state. This will assemble the transcription complex and initiate transcription of the 
luciferase-encoding gene. Luciferase will then be translated to protein, and the amount of 
luciferase produced can be determined by measuring the activity of the enzyme. When 
luciferase oxidizes the substrate luciferin to oxy-luciferin, light is emitted. This light can be 
measured at 560 nm and quantified, and correlated to the activation of the gmPparx receptor 
(Fig. 3.2). As β-galactosidase (β-gal) is continuously produced in the COS-7 cells, its activity 
can be used to normalize luciferase activities for variation in transfection efficacy between 
wells. β-gal hydrolyzes ONPG to ONP and galactose. ONP has a yellow color that absorbs light 






Figure 3.2: Overview of the principle behind the luciferase based GAL4-DBD UAS-system. COS-
7 cells are co-transfected with a reporter plasmid encoding fusion proteins of GAL4_DBD and the hinge 
and LBD of gmPparax, together with the luciferase reporter gene plasmid and a β-galactosidase-encoding 
control plasmid (the latter not shown in the figure). When the fusion protein is activated by an agonist it 
binds to the GAL-4-upstream activation sequence (UAS) in the luciferase reporter plasmid. This 
facilitates transcription of the luciferase enzyme, which further oxidizes luciferin to oxy-luciferin and 
light. The light emitted at 550-570 nm can be quantified with a luminometer. The illustration is modified 
from Madsen (2016).    
 
3.4.1 CONTROL OF LRA PLASMID INTEGRITY 
The effectiveness of transfection partly depends on plasmid quality. The integrity of the 
plasmids used in the LRA assay (receptor-, effector-, and control plasmids) was assessed with 
agarose gel electrophoresis (3.7) to ensure that the majority of the plasmids were in a 
supercoiled conformation, which is optimal for transfection into cells. The different 
conformations: circular nicked, linear and supercoiled were separated according to their 
migration distances in the gel, where supercoiled migrated the longest in the gel.  
 
3.4.2 CULTIVATION OF COS-7 CELLS  
COS-7 cells are an African green monkey kidney fibroblast-like cell line (Table 2.7). They 
grow in a monolayer in petri dishes, adhering to the surface. The cells were stored in freezing 
medium (Table 2.9) in liquid nitrogen. Aliquots were thawed at RT and resuspended in 10 mL 




resuspension medium was removed, and 10 mL fresh medium was added to the cells (Table 
2.10). The cells were seeded in 10 cm petri dishes and incubated at 37 oC, 5 % CO2. The cultures 
were subcultured when they reached 90-100 % confluency. Old medium was removed, the cells 
washed with 1X PBS (pH 7.4), detached through trypsination with 0.05 % Trypsin-EDTA for 
30 sec at RT, and incubated for 5 min at 37oC, 5 % CO2. Detached cells were resuspended in 
10 mL fresh growth medium and usually diluted 1:10 or 1:20 for further culturing.  
 
3.4.3 SEEDING OF COS-7 CELLS IN 96-WELL PLATES 
When COS-7 cells grown in culturing dishes reached 90-100 % confluency, the cells were 
washed, trypsinated and resuspended as described (3.4.2). Small equal volumes of cell 
suspension and of the dye, erythrosin-B, were mixed and cell density was determined using a 
Bürker hemocytometer (Marienfield) and a light microscope (Leica DM IL inverted 
microscope). COS-7 cells were seeded in 96-well plates using 100 µL growth medium with a 
final cell density of 5000 cells per well. The cells were incubated at 37 oC, 5 % CO2 for 24 hr.  
 
3.4.4 TRANSFECTION OF COS-7 CELLS  
Transient transfection introduces foreign DNA into a eukaryotic cell. The introduced DNA does 
not become part of the genome of the cell, and hence the plasmids will be expelled from the 
cell after some days. The Trans-IT LT1 kit (Mirus Bio) was used for the transfection of the 
COS-7 cells. For transfection, the ratio of plasmids was 1:10, with ten times more reporter- and 
control plasmid, than receptor plasmid (Table 3.5). The transfection reaction mixture (Table 
3.6) was incubated at RT for 30 minutes before COS-7 cell growth medium was added. The old 
medium in the 96-well plates were discarded and replaced with 101.4 µL fresh transfection 






Table 3.5: Amounts of plasmids added to 
each well in the 96-well plate during 
transfection 
Table 3.6: Composition of the TransIT-LT1 
transfection medium 
Plasmid Amount [ng] Component Amount per well 
(96-well plate) (μL) 










Plasmid mixture  
[1 μg/ μL] 
OptiMEM w/glutamax  
TransIT LT1 









3.4.5 EXPOSURE TO TEST COMPOUNDS 
The transfected COS-7 cells were exposed to test compounds in a seven (14 for WY-14643) 
concentration dilution series. Test compounds were dissolved in DMSO and serial diluted in 
exposure medium (Table 2.10 and 3.7) to 2X the exposure concentrations. The concentration 
of DMSO in exposure wells was 0.5%. The unexposed solvent control used was cell exposure 
medium containing 0.5 % DMSO. The transfection medium from the 96-well plate was 
discarded and replaced with 100 μL/well DMEM used for exposure (Table 2.10). Then 100 μL 
2X test compound solution was added per well, resulting in a 1X concentration of the test 
compounds in the plates. The plates were incubated for 24 hr at 37oC and 5 % CO2. 
 
Table 3.7: Compounds used for in vivo testing of agonistic effects on gmPparas 


















3.4.6 LYSIS AND ENZYMATIC MEASUREMENTS 
The exposure was terminated after 24 hr by removing the exposure medium and replacing it 
with 125 μL lysis reagent solution (Table 2.15) per well. The cells were lysed at RT for 30 min 
on a platform shaker. During lysis the cell membrane is disrupted to release the luciferase and 




for measuring of β-gal activity, while 50 μL of lysate was transferred to a white luminescence 
96-well plate for measuring of luciferase activity.  
For measurements of β-gal enzyme activities a β-gal reaction solution (Table 2.17) was 
prepared. To each well, 100 μL β-gal reaction solution was added. This was incubated for 
approximately 20 min, when the yellow color from the produced ONP appeared. The amount 
of ONP was measured as absorbance at 420 nm using the EnSpire 2300 Multimode Reader 
(PerkinElmer). For luciferase activity measurements a luciferase reaction solution (Table 2.19) 
was prepared. To each well, 100 μL were added and the measurements performed immediately. 
Luciferase activity was measured as emitted light with the EnSpire 2300 Multimode Reader 
(PerkinElmer). The recorded luciferase activities were adjusted for differences in transfection 
efficiencies by dividing luciferase activities with the corresponding β-gal activities using 
Microsoft Excel, and the activation profiles visualized using non-linear regression in GraphPad 
Prism. 
 
3.5 VIABILITY/CYTOTOXICITY ASSAY 
A viability assay was performed to assess if the test compounds used in LRA were toxic for the 
COS-7 cells. The viability assay was conducted with the same experimental conditions used in 
the LRA. A combination of two fluorometric assays, resazurin, and 5-carboxyfluorescein 
diacetate acetoxymethyl ester (CFDA-AM) were used to assess membrane integrity and 
metabolic activity. Resazurin is cell permeable and non-fluorescent. Within metabolic active 
cells it gets reduced by oxidoreductases to the fluorescent compound resorufin, measuring the 
metabolic activity in the COS-7 cells (Pace & Burg, 2015; H. X. Zhang, Du, & Zhang, 2004). 
CFDA-AM is also cell permeable and non-fluorescent. Within the cells CFDA-AM is 
hydrolyzed to fluorescent 5-carboxyfluorescein by intracellular esterases, and because only 
cells with the plasma membrane intact can maintain esterase activity this assay measures the 
integrity of the membrane (Bopp & Lettieri, 2008; Schreer, Tinson, Sherry, & Schirmer, 2005).  
Cells were seeded in 96-well plates as described in section 3.4.3. Samples were prepared in 
triplicates. After incubation, old media was discarded and replaced with 101.4 μL medium 
(Table 2.10). The cells were incubated for 24 hr, at 37 oC,  5 % CO2. The exposure was 
conducted as in LRA (3.4.5). After 24 hr exposure the medium was discarded, and the cells 




100 μL/well, and incubated at 37 oC, 5 % CO2 for 1 hr. Fluorescence were measured with 
EnSpire 2300 Multimode Reader (PerkinElmer) at 530/590 nm for resazurin and 485/530 nm 
for CFDA-AM.  
 
3.6 SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS 
(SDS-PAGE) AND WESTERN BLOTTING 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a method for 
separating proteins according to their size. Prior to the electrophoresis, proteins are denatured 
by boiling at 95oC in a sample buffer. The sample buffer contains a reducing agent (β-
mercaptoethanol) that breaks disulfide bonds in proteins, in addition to the anionic detergent 
sodium dodecyl sulfate (SDS). SDS binds to the proteins, promoting denaturation and coating 
the polypeptide chain, providing the proteins with an overall negative charge. The proteins will 
then be separated according to their mass-to-charge ratio. Where smaller proteins migrate faster 
through the gel, and larger protein migrate slower because of more resistance in the gel.  
 
3.6.1 PREPARATION OF CELL LYSATES FOR PROTEIN ANALYSIS  
COS-7 cells were seeded in 96-well plates (Section 3.4.4) and transfected (3.4.5). After 24 hr, 
old medium was discarded, and the cells washed with 100 μL 1X PBS per well. Subsequently, 
the cells were lysed with 20 μL lysis reagent per well (Table 2.26) and incubated on ice while 
shaking for five min. The lysate was pooled from 8 replicate wells and stored at -80oC.  
  
3.6.2 SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE) 
The MINI-PROTEAN Tetra Cell (Bio-Rad) was used for SDS-PAGE. Two gels were casted 
0.75 mm thick. One gel was used for protein immunoblotting, and one gel was used for protein 
staining with Coomassie Brilliant Blue. Each gel consisted of a 10 % separation gel, and a 4 % 
stacking gel (Table 2.27) casted on top of the separation gel. When the gels had polymerized, 
they were transferred from the casting unit to an electrophoresis chamber. The chamber was 
filled with 1X TGS buffer (Table 2.28). A Precision Plus Protein™ Prestained Protein 
Standards (Bio-Rad) was used as a protein size marker, and 5 μL of each protein sample was 




3.6.3 TOTAL STAINING OF PROTEINS IN USING COOMASSIE BRILLIANT BLUE 
For evaluation of the total protein content in the SDS-PAG, one gel was stained with Coomassie 
Brilliant Blue R250 staining solution with InstantBlue™ Coomassie Protein Stain (Expedeon) 
ON shaking at RT. The gel was rinsed with ddH2O for destaining. A picture was taken with 
ChemiDoc XRS+ (Bio-Rad).  
 
3.6.4 PROTEIN IMMUNOBLOTTING 
Protein immunblotting is an antibody-based method for the detection of specific proteins, and 
was used to assess the synthesis of gmPpar wts and mutants in the COS-7 cells. For protein 
immunoblotting the Mini Trans-Blot Electrophoretic Transfer Cell was prepared and used. A 
PVDF-membrane (6*9 cm) was activated by submerging in methanol for 20 sec, rinsed in 
dH2O, and soaked in transfer buffer for 10-15 min together with filter papers and sponges for 
the blotting sandwich. The sandwich was placed in an electrophoresis chamber together with a 
cooling unit. The chamber was filled with transfer buffer (Table 2.29), and the electroblotting 
was conducted for 1 hr at 100 V. The membrane was blocked ON in 5 % dry-milk in TBS-
tween (TBS-T) (Table 2.32) at 4 oC on a platform shaker. The dry-milk was washed away with 
TBS-T the next day (Table 2.31). Primary anti-GAL4-DBD antibody (Table 2.33) was diluted 
500 times in TBS-T and incubated on the membrane for 1 hr at RT while shaking. The 
membrane was washed in TBS-T to remove excess antibodies. The secondary antibody anti-
mouse IgG (Table 2.33) was diluted 1:2000 in 10 mL TBS-T and incubated on the membrane 
for 1 hr while shaking. Excess antibody was removed by washing with TBS-T. A second wash 
was performed with TBS buffer (Table 2.30). To visualize the immunoreactive proteins, the 
SuperSignal™ West Femto Maximum Sensitivity Substrate kit was used. A working solution 
of 2 mL was prepared and used according to the manufactures protocol. The bands were 
visualized with the ChemiDoc XRS+ (Bio-Rad).  
β-actin was used as a loading control since it is expressed in all eukaryotic cell types. To blot 
for beta-actin the membrane was washed with TBS-T. Then a primary antibody specific for β-
actin (Table 2.33) was diluted 1000 times in 10 mL TBS-T and incubated on the membrane for 
1 hr while shaking. The primary antibody was discarded and replaced with secondary antibody 
(Table 2.33) and incubated for another hour while shaking. The bands were visualized using 




3.7 AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis (AGE) is a method used to separate and visualize nucleic acids. 
Since nucleic acids are negatively charged they will migrate towards the positive pole through 
the gel when applying a current, which is carried by the ions in the running buffer. In this work, 
AGE was used to analyze PCR-products, or to assess plasmid DNA conformation. The agarose 
gel is added GelRed which interacts with the nucleic acids and allows visualization of DNA or 
RNA in the gel. 
A 0.7 % agarose solution was prepared with 0.5 X TBE buffer (Table 2.12). A gel with 30 mL 
agarose solution and 0.5 μL GelRed was prepared. This was left for solidification for 
approximately 20 min at RT. The gel was transferred to an electrophoresis chamber and soaked 
in 0.5 X TBE buffer. A 2-log DNA ladder was used as a size marker. In every run, 500 ng 
ladder and sample were loaded onto the gel, and the gels were run at 110 V for 30 min. The 
gels were visualized with ChemiDoc XRS+ (Bio-Rad). 
 
3.8 SANGER SEQUENCING  
For DNA sequencing, the Protocol BigDye v.3.1 kit was used. The reaction mixture was 
prepared (Table 3.8), and the amplification reaction performed (Table 3.9). After the reaction, 
10 μL DI-H2O was added to each reaction and submitted to the DNA Sequencing Facility at 
the Department of Biological Sciences, University of Bergen. 
 
Table 3.8: Reaction setup for one 
sequencing reaction.  
Table 3.9: Thermal cycle program for the 
sequencing reaction. 































4. RESULTS  
 
The main aim of this study was to investigate if structural differences originating from 
deviations in the AA sequence between gmPpara1 and gmPpar2 could contribute to the 
previously observed differences in activation profiles of the two wt gmPpara subtypes, 
including the observed discrepancies in activation when exposed to PFASs. To do so, four 
different mutants of gmPpar2 were constructed in order to make the primary structure more 
similar to the primary structure of gmPpara1. These resulting mutants were functionally 
characterized in a GAL4-UAS based LRA with selected agonists to study putative changes in 
the activation profiles by comparing the wt gmPpars and the constructed mutants. 
 
4.1 CONSTRUCTION AND SEQUENCING OF GMPPARA2 MUTANTS  
 
4.1.1 SDM DELETION IN THE HINGE REGION OF GMPPARA2 
The construction of the gmPpara2 mutants was based on a previously constructed plasmid 
encoding the wt gmPpara2 constructed previously (Söderström, 2017). Appropriate primers 
were designed and the SDM deletion experiment was performed as described in 3.2.3. Potential 
mutant plasmids were propagated in E. coli, purified, and subsequently sequenced to confirm 
if the desired 14 AA sequence was deleted from the hinge region of gmPpara2. In Figure 4.1, a 
multiple sequence alignment (MSA) of the deduced AA sequences after the SDM deletion 
experiment is shown. The MSA confirmed that the targeted region encoding AAs 266-279 had 
been deleted in two of the four plasmids. These plasmids were denoted gmPpara2_DEL-1 and 
gmPpara2_DEL-4, and gmPpara2_DEL-4 was used in the further work. 
 
Figure 4.1: Multiple sequence alignment of the gmPpara2_DEL constructed mutants. After SDM 
was performed, the plasmids were purified and sequenced at the Sequencing Facility at the Department 
of Biological Sciences, University of Bergen. The alignment of the translated plasmid sequences 
covering the relevant region was translated in silico using the ExPasy translate tool. Clustal-Omega 
(EMBL-BI) was used to align the sequences. The alignment was colored in Jalview according to AA 





4.1.2 SDM AMINO ACID SUBSTITUTION IN GMPPARA2_DEL 
gmPpara2_DEL-4 was further used for generating the mutants containing single AA 
substitutions in addition to the deleting the 14 AAs in the hinge region. Three different mutants 
were constructed, and hence, three different SDM experiments were performed with 
appropriate primers specifically designed for each experiment. Sequencing confirmed the 
successful construction of the mutants, which were denoted as: gmPpara2_DEL_G278>R278, 
gmPpara2_DEL_L286>H286 and gmPpara2_DEL_G278>R278+L286>H286.  
 
In Figure 4.2A the MSA for the first constructed mutant, gmPpara2_DEL_G278>R278, is 
shown. All of the sequenced plasmids contained the desired substitution, where  G266 had been 
changed to R266. For the further work gmPpara2_DEL_G>R-1 was chosen.  
 
In Figure 4.2B the MSA for the second constructed mutant, gmPpara2_DEL_L286>H286, is 
shown. The mutant gmPpara2_DEL_L286>H286 was constructed with the same approach as 
in the G278>R278 SDM experiment. The MSA show that all plasmids had been mutated 
successfully, and L286 had been changed to H286. gmPpara2_DEL_L286>H286-1 was used 
in the further work.   
 
Figure 4.2C shows the MSA for the third constructed mutants. The double mutant 
gmPpara2_DEL_G278>R278+L286>H286 was created with the same procedure as used for 
the SDM single AA substitution mutants, except that two mutagenic primer pairs were used 
simultaneously. The MSA show that G278 was mutated to encode R278 in plasmid two and 
four, while L286 had been changed to encode H286 in plasmids one, three, and four. Thus, the 
only successfully constructed mutant with both mutations present was plasmid number 4. 






Figure 4.2: Multiple sequence alignment demonstrating the amino acid substitutions made by 
SDM in gmPpara2_DEL. Three different SDMs were performed, and the plasmids were purified and 
sequenced at the Sequencing Facility at the Department of Biological Sciences, University of Bergen. 
Translations of AAs in the regions of interest were aligned in ClustalOmega (EMBL-BI), and the 
alignments were visualized in Jalview according to percentage identity. AAs targeted for substitutions 
have been indicated with red boxes. Alignment A shows the resulting plasmid from SDM of the 
gmPpara2_DEL_G278>R2787. Alignment B show the gmPpara2_DEL_L286>H286 SDM. Alignment 














4.1.3 OVERVIEW OF THE WT GMPPARAS AND THE CONSTRUCTED MUTANTS  
An MSA of the hinge and LBD regions demonstrate the differences in the AA sequences 
between gmPpara1, gmPpara2, and the constructed gmPpara2 mutants (Fig. 4.3). Both the 
deleted stretch of 14 AAs and the single AA substitutions were located in the hinge region of 
the receptor (yellow line). Furthermore, the conserved AAs in the LBD-region (green line) 
important for binding of the WY-14643 model-agonist in the canonical binding site  are 
highlighted in the MSA. The AAs important for binding of WY-14643 in the second allosteric 
binding site in hPPARa are also highlighted.  
Figure 4.3: Multiple sequence alignment of wild type and mutated Atlantic cod gmPpars. Plasmids 
encoding fusion proteins of GAL4-DBD and wild type gmPpara1 and gmPpara2, as well as mutant 
plasmids, were sequenced at the Sequencing Facility at the Department of Biological Sciences, 
University of Bergen and translated into protein sequences in silico using the ExPasy translate tool. The 
sequences were aligned with Clustal Omega (EMBL-EBI). Jalview was used to visualize the alignment 
according to percentage AA identity. Conserved AAs important for binding of WY-14643 in the 
canonical binding site in hPPARa are marked with pink boxes. The extended stretch of AAs in the hinge 
region of gmPpara2, and AAs that constitute the second binding site for WY-14643 in hPPARa are 
marked in red. The mutations that were made are indicated with dotted lines. The hinge region and LBD 




4.2 TRANSACTIVATION ANALYSES OF GMPPARAS AND GMPPARA MUTANTS 
 
4.2.1 PLASMID INTEGRITY CONTROL PRIOR TO LRA 
Plasmid integrity may affect the transfection-efficiency into mammalian cell lines. The plasmid 
integrities were therefore assessed with agarose gel electrophoresis prior to use in the LRA (Fig. 
4.4). The majority of the plasmids were present in the fastest migrating band in the gel, 
indicating that most plasmids were in the supercoiled conformation preferable for later 
transfection into COS-7 cells. The two less predominant higher molecular weight bands in the 
gel most likely represent plasmids in the circular nicked and linear conformation, respectively. 
Importantly, these results indicated that the plasmids in all preparations were largely 
supercoiled and suitable for transfection.  
 
Figure 4.4: Assessment of the conformation of plasmids used for LRA. Purified plasmids were 
separated in a 0.7 % agarose 0.5X TBA gel for 30 min at 200 V. 500 ng of each plasmid sample was 
applied to the gel. Reporter plasmid ((MH100)x4tk-luciferase (lane 1)), control plasmid (pCMV-β-
galactosidase (lane 2)), and receptor plasmids, (pCMX_GAL4_gmPpara1 (lane 3), 
pCMX_GAL4_gmPpara2 (lane 4), pCMX_GAL4_gmPpara2_DEL (lane 5), 
pCMX_GAL4_gmPpara2_DEL_G>R (lane 6), pCMX_GAL4_gmPpara2_DEL_L>H (lane 7) and 
pCMX_GAL4_gmPpara2_DEL_G>R+L>H (lane 8)), 500 ng of each plasmids and a 2-LOG ladder 
(New England Biolabs) was applied in each well.   
 
4.2.2 EVALUATION OF EXPRESSION OF GMPPARS AND GMPPAR MUTANTS IN COS-7 CELLS 
To confirm the translation and production of the GAL4_gmPpara fusion proteins in the COS7 
cells (both wt and constructed mutants), SDS-PAGE and protein immunoblotting were 
performed (Methods 3.6). Forty-eight hours after seeding, and 24 hours after transfection, the 
cells were harvested and lysed as described in 3.6.1. The cell lysates were separated with SDS-
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PAGE according to their MW. One parallel gel was Coomassie-stained to verify proper 
separation of the polypeptides and to visualize total protein content (Fig. 4.5A). The other gel 
was used for protein immunoblotting for detection of the GAL4-gmPparx fusion proteins using 
an anti-GAL4-DBD antibody (Table 2.33), (Fig. 4.5B). The expression of β-actin was used as 
a loading control and was detected using an anti-β-actin antibody (Fig. 4.5C) (3.6.4). The 
Coomassie-stained gel showed that the proteins were separated successfully during the 
electrophoresis, and indicated that similar amounts of protein was applied in each well (Fig. 
4.5A). The membrane used for immunoblotting was first probed with the primary anti-GAL4 
antibody in the first round of blotting, and anti-β-actin in the second round of blotting (3.6.4). 
The fusion proteins, including gmPpara1, gmPpara2, gmPpara2_DEL, gmPpara2_DEL_G>R, 
gmPpara2_DEL_L>H, and gmPpara2_DEL_G>R+L>H were detected as immunoreactive 
bands around 50 kDa in cell lysates prepared from the transfected COS-7 cell (Fig. 4.5B). The 
wt gmPpara2 (GAL4-DBD-gmPpara2-hinge+LBD) appear to migrate slower in the PA-gel, 
which corresponds well to their predicted MWs (Table 4.1). As expected, no immunoreactive 
bands were detected in the non-transfected cells using the anti-GAL4-DBD antibody, 
demonstrating that gmPpara-proteins were only expressed in COS7 cells transiently transfected 
with plasmids encoding GAL4-gmPpara fusion proteins. β-actin was detected in all samples 
around 42 kDa in both untransfected and transfected cell lysates. 
 
Table 4.1: The predicted MWs of gmPparx fusion proteins 


















Figure 4.5: Detection of the fusion proteins GAL4-gmPpars in transfected COS-7 cells with 
protein immunoblotting. The COS-7 cell lysates were separated on two 10 % PA gels. (A) SDS-PAG 
stained with Coomassie Brilliant Blue. The corresponding PVDF-membrane were treated with (B) 
mouse anti-GAL4 (diluted 1:500 in TBS-Tween) and sheep-anti-mouse-IgG (diluted 1:2000 in TBS-
Tween), and (C) with mouse anti-β-actin and sheep-anti-mouse-IgG. Lane 1: untransfected COS-7 
cells. COS-7 cells were transfected with the following receptor plasmids; pCMX_GAL4_gmPpara1 
(lane 2), pCMX_GAL4_gmPpara2 (lane 3), pCMX_GAL4_gmPpara2_DEL (lane 4), 
pCMX_GAL4_gmPpara2_DEL_G>R (lane 5), pCMX_GAL4_gmPpara2_DEL_L>H (lane 6) and 
pCMX_GAL4_gmPpara2_DEL_G>R+L>H (lane 7). As a size marker, the Precision Plus Protein™ 










4.2.3 ACTIVATION OF WT GMPPARS AND GMPPAR MUTANTS EXPOSED TO VARIOUS 
AGONISTS 
Initially, the activation of the wt gmPpara1 and gmPpara2 by the WY-14643 model agonist was 
investigated with the GAL4-UAS based LRA assay. Exposure of COS-7 cells expressing 
gmPpara1 to increasing concentrations of WY-14643 produced a dose-dependent increase in 
luciferase activity to a maximum level of 23.6-fold higher than solvent-exposed cells 
(p≤0.0001) (Fig. 4.6, Table 4.2). In cells expressing gmPpara2, the maximum increase in 
luciferase activity was 8.8-fold (p≤0.046) after WY-14643 exposure (Table 4.2). The EC50 
values for gmPpara1 and gmPpara2 were estimated to be 56.5 μM (53.4-60.0, 95% CI) and 97.5 
μM (92.4-103.8, 95% CI), respectively (Table 4.3).  
 
 
Figure 4.6: Activation of gmPpara1 and gmPpara2 by WY-14643. COS-7 cells were co-transfected 
with the receptor plasmids (gmPpara1 or gmPpara2), reporter plasmid ((MH100)x4tk-luciferase) and 
control plasmid (pCMV-β-galactosidase). After transfection cells were exposed to increasing 
concentrations of WY-14643 for 24 hr. The activation of the GAL4-gmPpara1/a2 receptor is shown as 
relative fold change in luciferase activity in WY-14643-exposed cells compared to the solvent exposed 
cells (0.5 % DMSO). Three individual experiments were performed, each with exposures in triplicates 




























4.2.4 ACTIVATION OF WT AND MUTATED GMPPARS WHEN EXPOSED TO WY-14643 
The GAL4-UAS-based LRA was also used to assess the effect of the mutations on the activity 
of gmPpara2 when exposed to WY-14643 and a selected set of PFASs. Comparison of 
activation profiles of gmPpara2 mutants and wt gmPpara2 when exposed to WY-14643 
demonstrated several differences (Fig. 4.7). In general, the response mediated by the gmPpara2 
mutants was much stronger (higher efficacy) than responses mediated by the wt gmPpara2 (Fig. 
4.10A, Table 4.2). The constructed mutants had a distribution of their maximum fold activation 
between 171- and 134-fold induction, in the following order: gmPpara2_DEL > 
gmPpara2_DEL_G>R+L>H > gmPpara2_DEL_G>R > gmPpara2_DEL_L>H (Table 4.2). In 
comparison, activation of the wild type gmPpara2 reached a maximum of approximately 9-fold. 
All of the constructed mutants had at least 15 times stronger activation than gmPpara2, and 6 
times stronger activation than gmPpara1. The calculated EC50-values (Table 4.4) demonstrated 
that WY-14643 was a significantly more potent agonist to different gmPpara2 mutants (Table 
4.5) compared to the wt gmPpara2, except for the mutant gmPpara2_DEL_L>H. However, 
WY-14643 was the most potent agonist for gmPpara1, which produced the lowest EC50 value. 
The potency of WY-14643 towards the gmPpara2 mutants were mostly not statistically 
different from each other. Although the responses of the wt and constructed mutants were 
different regarding magnitude (efficacy, Emax) and EC50, the activation of the receptors all 
starts at relatively low and similar concentrations of WY14643, as illustrated by LOECs ranging 
between 9-27 μM (Fig. 4.7 A, Table 4.4). The Emax-values determined for the receptors can be 
statistically grouped into three (Table 4.3): 1) The maximum response for all constructed 
mutants were significantly different from that of wt gmPpara2. 2) The maximum response of 
gmPpara2_DEL was significantly different from all three mutants containing the additional 
single or double AA-substitutions. 3) The three mutants containing the single or double AA 
substitutions did not have significantly different Emax-values from each other. The EC50 values 
of the different gmPpara2 mutants were statistically different from wt gmPpara2 (Table 4.4, 
Table 4.5), and the mutants had EC50 values in the range between gmPpara1 and gmPpara2. 
Moreover, the EC50 values of gmPpara2_DEL_G>R and the EC50 value of 
gmPpara2_DEL_L>H were significantly different from each other. None of the other EC50 





Figure 4.7: Activation profiles for different wt and mutant gmPpars exposed to WY-14643, PFOA, 
PFNA and PFOS. The dose-response curves (A-D) show the activation profiles of gmPpars exposed 
to WY-14643 and three selected PFASs, including PFOA, PFNA, and PFOS. COS-7 cells were seeded 
and co-transfected with the receptor plasmids (gmPpara1, gmPpara2, gmPpara2_DEL, 
gmPpara2_DEL_G>R, gmPpara2_DEL_L>H, or gmPpara2_DEL_G>R+L>H), reporter plasmid 
((MH100)x4tk-luciferase) and control plasmid (pCMV-β-galactosidase). After transfection cells were 
exposed to increasing concentrations of the different test compounds as indicated for 24 hr. Activation 
of GAL4-gmPpars is shown as fold change in luciferase activity in exposed cells compared to cells 
exposed to solvent control (0.5 % DMSO).  Each experiment was performed three times, with three 
technical replicates (n=9). Non-linear regression (GraphPad, Prism) was used to create the dose-
response the curves. 
 
4.2.5 ACTIVATION OF WT AND MUTATED GMPPARAS WHEN EXPOSED TO PFOA, PFNA AND 
PFOS 
PFOA and PFNA induced a 7.6-fold (p<0.0001) and a 2.7- fold (p<0.0001) activation of 
gmPpara1, respectively, when compared to the solvent control (Fig. 4.7 B and C, Table 4.1). 
EC50-values were not estimated since a stable plateau of activation was not reached. For 
gmPpara2 and the constructed gmPpara2 mutants, no activation was observed by either PFOA 
or PFNA. PFOS did not activate any of the wt gmPpars or the constructed mutants (Fig. 4.7 D). 
For PFNA and PFOS an apparent decrease in the luciferase signal at the higher concentrations 












































































































Table 4.2: Maximum response (Emax) and lowest observed effect concentration (LOEC) produced 
by WY-14643. 















































WY-14643 160 8.8,           
8.2-9.4 
<0.0001 11.0 0.9 0.046 
gmPpara2_DEL WY-14643 128 171.1,    
161.2-183.4 
<0.0001 13.7 1.3 0.0035 
gmPpara2_DEL
_G>R 
WY-14643 160 140.6,   
130.2-154.6 
<0.0001 17.2 1.4 0.026 
gmPpara2_DEL
_L>H 
WY-14643 160 134.1,   
124.0-148.6 
<0.0001 21.5 1.3 0.048 
gmPpara2_DEL
_G>R+L>H  
WY-14643 160 144.5, 
137.0-153.7 
<0.0001 8.9 1.2 0.0007 
 
Table 4.3: Statistical differences in Emax between gmPparas exposed to WY-14643.
 










Table 4.4: EC50 values for gmPpars activated by WY-14643, PFOA and PFNA. 
Receptor  Agonist Half maximal Effective 
concentration 50 (EC50 




















Table 4.5: Statistical differences in EC50 between gmPparas exposed to WY-14643.
 
A one-way ANOVA and Sidaks multiple comparisons test was used to test for statistical significance. 
 
4.2.6 CYTOTOXIC EFFECTS IN COS-7 CELLS AFTER EXPOSURE TO TEST COMPOUNDS 
To monitor if any of the PFASs used in the LRA were cytotoxic, and hence affected the viability 
of the COS-7 cells, the effects of the test compounds (PFOA, PFNA and PFOS) on the cells 
metabolic activity and membrane integrity were assessed. In a previous study it was shown that 
WY-14643 did not affect COS-7 viability, hence the cytotoxicity test was not repeated in this 
thesis (Söderström, 2017). In Figure 4.8, the measured metabolic activities (4.8 A-C), and the 
plasma membrane integrities (4.8 D-F) are shown. As expected, COS-7 cells exposed to 0.5 % 
Triton X-100 (used as a positive control) showed a distinct reduction in metabolic activity to 8 
% of non-exposed cells, while plasma membrane permeability was reduced to 2 %. For PFOA, 
a significant decrease in metabolic activity, as well as a reduction of plasma membrane 
integrity, were observed for concentrations between 23-267 μM. In COS-7 cells exposed to 
PFNA, a dose-dependent decrease in metabolic activity was observed for exposures of 79-267 
μM, with the viability decreasing from 94 % to 81 %. With regards to plasma membrane 
integrity, PFNA exposure showed a dose-dependent decrease at exposures of 35-267 μM, with 
the membrane integrity decreasing from 84 % to 56 %. Similarly, PFOS induced a small dose-




with the activity decreasing from 93 % to 81 %. PFOS exposure also caused a decrease in the 
plasma membrane integrity of COS-7 cells.  
 
 
Figure 4.8: Viability of COS-7 cells after exposure to different PFAS. COS-7 cells were exposed to 
the same range of concentrations of PFOA, PFNA, and PFOS, as used in the LRA. Exposure to DMEM 
with 0.5 % DMSO (solvent control) or 0.5 % Triton X-100 were used as a negative and positive control 
for cytotoxicity, respectively. Cytotoxic responses were defined as a decrease in the fluorescent signal 
compared to the cells exposed to 0.5 % DMSO, which was defined as 100 % and indicated as a dotted 
line in the graphs. (A-C) Upper panels show the metabolic activity using resazurin measurements. (D-
F) Lower panels show the plasma membrane integrity as measured by CFDA-AM. Significance is 















The family of PPAR receptors has been found to be key regulators of the lipid homeostasis, 
energy utilization and lipid storage, with three different main subtypes found in vertebrates, i.e. 
PPARa, PPARd, and PPARg (Desvergne & Wahli, 1999). Some teleosts, including Atlantic 
cod, possess two Ppara subtypes, denoted Ppara1 and Ppara2 (Bertrand et al., 2007; Maglich et 
al., 2003; Metpally et al., 2007) This thesis has focused on the Atlantic cod gmPpara1 and 
gmPpara2. Notably, the gmPpara1 receptor was previously shown to be activated by some 
PFASs, including PFOA, PFNA and PFHxS. The Atlantic cod Ppara2 was not activated by any 
of these compounds. Moreover, both a lower efficacy and a lower potency of the control agonist 
WY-14643 on gmPpara2 were observed compared to the gmPpara1 receptor (S.Söderstrøm, 
2017). Importantly, distinct differences in the primary structures of gmPpara1 and gmPpara2 
have been observed, and the functional implications of some of these differences in regard to 
ligand recognition and activation have been explored in this thesis. 
 
In this study four different gmPpara2 mutants have been constructed. These mutants, in addition 
to the wt gmPpara1 and gmPpara2 receptors (Table 2.5), were exposed to the PPARa model-
agonist WY-14643 and selected PFASs (PFOA, PFNA and PFOS), and characterized using a 
luciferase-based reporter gene assay (LRA) in COS-7 cells. This assay was used to investigate 
the ability of the test compounds to activate the fusion protein GAL4-DBD-gmPparx-
hinge+LBD. The synthesis of the fusion proteins in COS-7 cells was examined with SDS-
PAGE and protein immunoblotting. The cytotoxicity of the compounds in COS-7 cells was 
monitored in a cytotoxicity assay.   
 
CONSTRUCTION OF GMPPARA2 MUTANTS AND EXPRESSION IN COS-7 CELLS 
The first mutant, gmPpara2_DEL, was constructed based on recent in silico modeling data 
which suggested that the 14 additional AA in the gmPpara2 hinge region contributed to the 
observed differences in activation profiles of gmPpara1 and gmPpara2 when exposed to WY-
14643 and certain PFAS congeners. The mutants with single AA substitutions, in addition to 




hPPARa, suggesting that four AAs, in which two of these differ between hPPARa/gmPpara1 
and gmPpara2, play an important role in binding of WY-14643 to a non-canonical second 
binding site (Bernardes et al., 2013). The first single AA mutated in gmPpara2_DEL was G278, 
an aliphatic, hydrophobic and non-reactive AA (Petrat, Boengler, Schulz, & de Groot, 2012). 
G was replaced with R278 a hydrophilic, positively charged AA, which can participate in both 
hydrophilic and hydrophobic interactions (Armstrong, Mason, Anderson, & Dempsey, 2016). 
Arginine is also the AA present in this position in the gmPpara1 receptor. The second AA 
mutated was L286, also an aliphatic, hydrophobic and non-reactive AA (Kathuria, Chan, 
Nobrega, Özen, & Matthews, 2016). This AA was changed to H286, a basic, positively charged 
AA (Ingle, 2011), which was present in this position in both the gmPpara1 and the hPPARa. 
Thus, both the 14 AA deletion and the additional two AA substitutions created gmPpara2 
mutants that were more similar to gmPpara1. All of the constructed mutants were successfully 
constructed with SDM and verified with DNA sequencing.  
 
Protein immunoblotting, using an antibody towards GAL4-DBD, was used to investigate if the 
gmPpar fusion proteins were produced in the transiently transfected COS-7 cells (Fig.4.2.3). 
While β-actin was detected in all cell lysates, the GAL4-reactive proteins were only detected in 
transfected cells, indicating a successful production of the GAL4-DBD-gmPparax-hinge+LBD 
proteins. Similar amounts of gmPpars were apparent in the different cell lysates, suggesting 
that the mutations did not significantly affect expression of the gmPpara variants in the COS7-
cells. 
 
ACTIVATION OF GMPPARS IN THE LUCIFERASE REPORTER GENE ASSAY 
 
WHY USE THE LUCIFERASE REPORTER GENE ASSAY? 
Reporter gene systems have commonly been used as a tool to study ligand-activation of NRs, 
as the expression of the reporter gene is a direct result of receptor activation (Paguio, Stecha, 
Wood, & Fan, 2010). The method allows for high throughput screening, and comparison of 
different ligands regarding their efficacy and potency (Wolf, Takacs, Schmid, Lau, & Abbott, 
2008). In GAL4-UAS-based LRAs, the ligand-binding domain (LBD) is utilized. The activity 




as there is a fixed ratio between emitted photons and reacting substrate molecules (Branchini et 
al., 2018). The luciferase assay used in this study was a UAS/GAL4 system. The GAL4 system 
reduces potential interference from endogenous NRs present in the cell lines used. The 
overexpressed chimeric receptor also seems in general to be less toxic to the cells. Furthermore, 
with the GAL4-system, the activation of the receptor does not depend on the natural 
dimerization partner of the receptor tested (Chen, Xie, Agler, & Banks, 2003; Paguio et al., 
2010). 
 
GMPPARA2 MUTANTS WERE MORE SUSCEPTIBLE TO ACTIVATION BY WY-14643 
WY-14643 is a well-known agonist for PPARa, which previously has been found to be one of 
the most potent exogenous ligands for PPARa in mammalian species (Bernardes et al., 2013; 
Peters, Cattley, & Gonzalez, 1997; J. Z. Zhang & Ward, 2010). Ppara in fish have also shown 
to be activated by WY-14643 (Laprairie, Denovan-Wright, & Wright, 2016; Leaver et al., 
2005). The constructed mutants were hypothesized to have WY-14643 activation profiles more 
similar to those of gmPpara1, as the mutants had been changed to be more similar to this 
subtype. However, when the gmPpara2 mutants were exposed to WY-14643, an unprecedented 
strong increase in efficacy compared to the wt gmPparas was observed. The WY-14643-
induced response (Emax) was significantly higher in cells expressing the constructed mutants 
compared to the wt gmPpara1 and gmPpara2. When comparing the activation profiles in more 
detail, the gmPpara2_DEL was significantly different from the three other constructed mutants 
(Table 4.4), where gmPpara2_DEL produced the highest efficacy (171-fold increase compared 
to unexposed cells, with an estimated EC50=84.8 μM). For the mutants containing the 
substituted AAs in addition to the deletion, the fold activation differed between 134-145, but 
none of these were significantly different from each other (Table 4.3). The EC50 values were in 
the same range of gmPpar2_DEL, and estimated to be 85.5 μM, 79.6 μM and 92.3 μM, for 
gmPpara2_DEL_G>R+L>H, gmPpara2_DEL_G>R, and gmPpara2_DEL_L>H, respectively. 
These results show that the potencies of WY-14643 towards the constructed mutants were 
between the potency determined for gmPpara1 and gmPpara2 (Table 4.4 and 4.5), while the 
efficacy produced by WY-14643 was about 15 times higher than for gmPpara2, and 6 times 





Notably, this demonstrates that removing the 14 AAs in the hinge region made a significant 
impact on the activation of the gmPpara2 receptor, especially with regard to efficacy. The 
higher efficacy of the gmPpara2_DEL mutation might be caused by structural or 
conformational changes in the receptor, potentially increasing its stability by shortening the 
predicted loop region between H1 and H3 as suggested by Bernandes et al (Bernardes et al., 
2013). This loop extension is situated near both the ligand binding pocket and the coactivator 
binding site. Removal of this region may have increased the affinity of WY-14643. Moreover, 
the affinity of cofactors may also have been changed, where the AA deletion may have 
promoted the binding and recruitment of cellular cofactors. The mutants with additional AA 
substitutions seemed to have an opposite effect on the efficacy of WY-14643 than initially 
hypothesized, since the activation in these mutants were slightly reduced compared to the 
gmPpara2_DEL mutant. It must be emphasized that it is currently not known if this second 
binding site at all is capable of binding to WY-14643 in the gmPpara variants. As no increased 
efficacy or potency were observed when “restoring” this putative binding site in the 
gmPpar_DEL mutant, it may suggest that a second WY-14643 molecule is not recruited to this 
site. However, it cannot be excluded that binding of a second WY-14643 to this non-canonical 
binding site occurs, but the lowered efficacies are due to other conformational changes induced 
by the single AA mutations. 
 
MUTATIONS DID NOT AFFECT SUSCEPTIBILITY TO PERFLUORINATED COMPOUNDS  
Previously, it was shown that gmPpara1 could be activated by some PFASs, including PFOA 
and PFNA, but not gmPpara2. Because of time constraints only PFOA, PFNA and PFOS, were 
chosen to assess if the mutated gmPpara2 subtype could be activated by PFAS congeners. These 
three PFASs have also been most commonly used in the industries and consumer products 
(Jantzen et al., 2016).  
 
The cytotoxicity of the PFASs used in the ligand activation assay was assessed for the COS-7 
cells (Fig. 4.8). The metabolic activity was mostly reduced by PFOA (lowest 66 %), but also 
PFNA and PFOS showed some decrease in the metabolic activity. The membrane integrity was 
gradually reduced by all PFASs, and PFNA demonstrated the largest impact on the integrity. 




luciferase activity when assessing for putative agonistic effects of the receptors. PFOA and 
PFOS were found to exert some cytotoxic effects in HepG2 cells (Florentin, Deblonde, Diguio, 
Hautemaniere, & Hartemann, 2011), but to a lesser extent than observed in this study. However, 
the cell lines are different (e.g. kidney vs. liver), which may contribute to the observed 
differences in the decrease in viability.  
 
When the six different gmPpara variants were exposed to the PFAS molecules, PFOA and 
PFNA managed to activate gmPpara1 only. This activation of the wt gmPpara1 was as in line 
with previous findings. PFOA and PFNA produced a 7.6-fold and 2.7-fold activation of 
gmPpara1, respectively. For both the wt gmPpara2 and the constructed mutants, no activation 
of PFASs were observed. For PFOS, no activation was observed for any of the gmPparas, which 
also is in accordance with previous findings (S.Söderstrøm, 2017). These results suggest that 
removing the additional stretch of 14 AAs in the gmPpara2 hinge region does not affect the 
activation of gmPpara2s by PFASs in vitro. The hypothesis was that when the sequence of 
gmPpara2 became gradually more similar to gmPpara1, it would be activated by PFOA and 
PFNA. As this was not the case, it further indicates that neither the 14 AA deletion, nor the 
mutation of G278 and L286, were sufficient for constructing a PFAS-sensitive variant of 
gmPpara2. 
 
Importantly, the mutations made in this study were not sufficient to provoke activation when 
the constructed mutants were exposed to selected PFASs. Hence, the reason for the different 
activation profiles must be attributed to differences located elsewhere in the protein structures. 
Importantly, there are still differences in the primary structures of gmPpara1 and gmPpara2 that 
were not assessed in this thesis. These are mainly single AA substitutions, but especially in the 
hinge region, such as from E190 to A199 in gmPpara1, there are larger stretches of AAs that 
differ between the two subtypes. Also, the region from V251 to G260 in gmPpara2 (Fig. 4.3), 
which is just before the extended region removed in this study, contains several AA differences 
that distinguish the two receptors. These may also contribute to the different activation profiles 






Four different mutants, gmPpara2_DEL, gmPpara2_DEL_G>R, gmPpara2_DEL_L>H and 
gmPpara2_DEL_G>R+L>H, were successfully constructed to investigate the role of a 14 AA 
indel in the hinge region, and a putative secondary WY-14643 binding site, in the ligand 
activation of Atlantic cod gmPparas. When the gmPpara2 mutants were exposed to WY14643, 
the potencies were calculated to be between the EC50-values determined for the two wt 
gmPparas. This means that the constructed mutants became more potent towards WY-14643. 
However, the efficacy, i.e. the fold activation produced by the gmPpara2 mutants, was higher 
than expected. The fold induction ranged between 134-171 for the different mutants, which was 
about 15 times higher than for wt gmPpara2, and 6 times higher than gmPpara1. This 
demonstrates that deleting the 14 AAs in gmPpar2 had the most impact on the activation profile, 
which may have increased the affinity towards WY-14643, or enhanced the stability of the 
receptor in an active conformation. The mechanistic and functional implications of the single 
AA mutations of the putative second binding for WY-14643 need to be elucidated further. 
Importantly, neither of the mutations performed affected the ability of gmPpara2 to be activated 















In this study some questions were answered, but many others were raised. For further studies 
in silico structure modeling and docking analysis of the constructed mutants when exposed to 
WY-14643 would be useful and helpful to understand why the mutants are more responsive 
than the wt gmPparas, while the potency is more consistent and in the range between gmPpara1 
and gmPpara2. Recombinant expression and purification, followed by crystallization of the 
receptor mutants when bound to WY-14643 could be very useful. This could provide an 
understanding of why the mutants were so highly activated, which AAs are involved in the 
binding of WY-14643, how it is positioned in LBP, and if the predicted putative secondary 
binding site will bind WY-14643. Studying the gmPpara receptor exposed to WY-14643 and 
the selected PFASs with nuclear magnetic resonance (NMR) could also be useful, and provide 
more information regarding how the ligand binding occur, ligand binding affinities, 
stabilization and conformation of the protein structure, and the cofactor binding site. 
 
In this thesis the extended region in the loop between H1 and H3 in gmPpara2 has been 
investigated and two AAs important for WY-14643 binding in the second allosteric binding 
site in hPPARa have been investigated in gmPpara2. There are still some sequence differences 
between gmPpara1 and gmPpara2. These changes can also be investigated and studied further 
with SDM to assess if they have an impact on both ligand binding of WY-14643 and the PFASs. 
More PFASs could also be included in the exposure, or a mixture of different PFASs could be 
used for exposure of the receptors in LRA to study if the PFASs activate differently, or activate 
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Functional Characterization of Atlantic Cod (Gadus morhua) 
Peroxisome Proliferator-activated Receptor alpha 1 and alpha 2
Methods
Site-directed mutagenesis (SDM) was used to obtain the desired mutants of
gmPpara2, and LRA was used to measure the receptor activity when exposed to
the ligand WY-14643. When doing SDM, first the insertion in gmPpara2 was
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Background and aims 
Atlantic cod (Gadus morhua) has four paralogous peroxisome proliferator-activated
receptors (Ppars), including Ppar alpha 1 and 2, Ppar beta/delta, and Ppar gamma.
Ppars are ligand activated transcription factors that are members of the superfamily
of nuclear receptors. The different Ppars have important, but distinct, roles in
energy metabolism (1, 2). Previously, we have demonstrated that gmPpara1 could
be activated by some exogenous compounds, including the hsPPARA model-
agonist WY-14643, and the perfluoralkylated substances (PFASs) PFHxA, PFOA,
PFNA and PFHxS. gmPpara2 were also activated by WY-14643, but none of the
PFASs (2).
The protein sequences of gmPpara1 and gmPpara2 have some important
differences. The gmPpara2 has an insertion of 14 amino acids in the hinge region.
In addition, two of the amino acids important for binding of WY-14643 in a second
“allosteric” binding site are also changed in gmPpara2. We hypothesize that these
differences cause the observed discrepancies in the activation profiles of
gmPpara1 and gmPpara2. In this study gmPpara2 has been mutated to become
structurally more similar to gmPpara1, and a luciferase reporter gene assay (LRA)
has been used to assess ligand activation of the produced Ppara2 mutants.
Conclusions and further work
All the gmPpara2 mutants were shown to be activated by the known agonist WY-14643. Preliminary results indicates that the deletion of the 14 AA increase the efficacy but
not the potency of the WY-14,643 response. The G93R substitution appear to slightly increase the efficacy, while the L102H substitution appear to lower efficacy and
increase potency. More experiments are needed to obtain enough data for statistical analysis. Further work include to study if the substitution and/or amino acids 93 and 57
explain the observed differences in responses of gmPpara1 and gmPara2 exposed to PFASs.
REFERENCES 1. Tyagi et.al. (2011) J Adv Pharm Tech Res 2. S. Söderström (2017) Environmental Toxicology
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Luciferase Reporter Gene 
Assay with Ppara2 mutants
Figure 1: Workflow and methods. GAL4-DBD/UAS based reporter gene assay with the
Ppar ligand binding domain. Activation of Ppar by a ligand (LIG), which promotes
transcription of the luciferase gene. The luciferase protein converts the substrate luciferin
to oxyluciferin, in a reaction that produces light that can be measured with a luminometer.
Table 1: Potency and efficacy of gmPparas exposed to WY-14643. EC50 and Emax values for 
gmPpars exposed to WY-14643 are shown.
Figure 2: Multiple sequence alignment of the protein sequences of the wild 






































- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - MN K A K AR T I L T G K T S T P P
MGGR S E A EQ T L T P PDH K V L VQQ I HQ A YMRN F SMN KDR AR L I L T G K T SR P P
MGGR S E A EQ T L T P PDH K V L VQQ I HQ A YMRN F SMN KDR AR L I L T G K T SR P P
MGGR S E A EQ T L T P PDH K V L VQQ I HQ A YMRN F SMN KDR AR L I L T G K T SR P P
MGGR S E A EQ T L T P PDH K V L VQQ I HQ A YMRN F SMN KDR AR L I L T G K T SR P P
MGGR S E A EQ T L T P PDH K V L VQQ I HQ A YMRN F SMN KDR AR L I L T G K T SR P P
F V I HDMD T L Q L A EQ T L V A KMVG TGGGG - - - - - - - - - - L L - - - DR E A E AR I
F V I HDME T F Q A A EQ T L E VRGA AG P S PG P VQG L T AG K E L L V EG PGE A E AR L
F V I HDME T F Q A A EQ T L E VRGA AG P S PG - - - - - - - - - - - - - - G PG E A E AR L
F V I HDME T F Q A A EQ T L E VRGA AG P S PG - - - - - - - - - - - - - - G PR E A E AR L
F V I HDME T F Q A A EQ T L E VRGA AG P S PG - - - - - - - - - - - - - - G PG E A E AR L
F V I HDME T F Q A A EQ T L E VRGA AG P S PG - - - - - - - - - - - - - - G PR E A E AR L
FHCCQC T S V E T V T E L T E F A K S V PG F A E L D L NDQV T L L K YG V Y E A L F AML A
F L CCQ S A S V E A V T E L T E F A KN I PGF L H L D L NDQV T L L K YGV Y E A L F T L L A
F L CCQ S A S V E A V T E L T E F A KN I PGF L H L D L NDQV T L L K YGV Y E A L F T L L A
F L CCQ S A S V E A V T E L T E F A KN I PGF L H L D L NDQV T L L K YGV Y E A L F T L L A
FHCCQ S A S V E A V T E L T E F A KN I PG F L H L D L NDQ V T L L K YGV Y E A L F T L L A
FHCCQ S A S V E A V T E L T E F A KN I PG F L H L D L NDQ V T L L K YGV Y E A L F T L L A
SCMN KDG L L V A YG AG F I T R E F L K S L RR P F SDMME P K F Q F AMR FN A L E L DD
SCMN KDG L L V ARGGG F I T R E F L K S L RR P F SDMME P K FQ F A T R FN A L Q L DD
SCMN KDG L L V ARGGG F I T R E F L K S L RR P F SDMME P K FQ F A T R FN A L Q L DD
SCMN KDG L L V ARGGG F I T R E F L K S L RR P F SDMME P K FQ F A T R FN A L Q L DD
SCMN KDG L L V ARGGG F I T R E F L K S L RR P F SDMME P K FQ F A T R FN A L Q L DD
SCMN KDG L L V ARGGG F I T R E F L K S L RR P F SDMME P K FQ F A T R FN A L Q L DD
SD L A L F V A A I I CCGDR PG L VN VGH I ERMQ EN I VQ V L R L H L L ANHQDD T F L
SD L A L F V S A I I CCGDR PG L VN A S L V ER L Q E S V VQ A L Q L H L V ANHRDN A F L
SD L A L F V S A I I CCGDR PG L VN A S L V ER L Q E S V VQ A L Q L H L V ANHRDN A F L
SD L A L F V S A I I CCGDR PG L VN A S L V ER L Q E S V VQ A L Q L H L V ANHRDN A F L
SD L A L F V S A I I CCGDR PG L VN A S L V ER L Q E S V VQ A L Q L H L V ANHRDN A F L
SD L A L F V S A I I CCGDR PG L VN A S L V ER L Q E S V VQ A L Q L H L V ANHRDN A F L
F P K L L QK L AD L RQ L V T EH AQ L VQE I K K T ED A S L H P L L QE I YRDMY
F P K L L QK L AD L R E L V T EH AQ L VQD I E T T ED T S L H P L L QE I YRDMY
F P K L L QK L AD L R E L V T EH AQ L VQD I E T T ED T S L H P L L QE I YRDMY
F P K L L QK L AD L R E L V T EH AQ L VQD I E T T ED T S L H P L L QE I YRDMY
F P K L L QK L AD L R E L V T EH AQ L VQD I E T T ED T S L H P L L QE I YRDMY

















































































Figure 3: Activation profiles of the wild type gmPpars (A) and gmaPpara2 mutants (B) when exposed to 
WY-14634. WY-14643 structure is shown. 
A B








EC50 (μM) 88.0 116.0 121.4 115.5 71.6 81.7
Emax (fold) 45.3 33.4 179.7 204.0 74.0 127.6
Results and discussion
SDM produced the desired mutants, as can be seen in the multiple sequence alignment (Figure 2). The activation profiles of gmPpara1 and gmPpara2 wild types and
mutants with the WY-14643 ligand were assessed with the LRA (Figure 3). The EC50 and Emax of the the different mutants were estimated from a dose-response curve
generated by non-linear regression using GraphPad Prism 7.0 (Table 1).
Workflow
Luciferase reporter gene assay
